In patients with an atherosclerotic CVD event or at intermediate to high risk for one who were on statin therapy, a novel ...
Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non ...
GlobalData on MSN
MSD boasts data for oral PCSK9 inhibitor as add on therapy
GlobalData’s patient-based forecast predicts that MSD’s enlicitide will achieve blockbuster status in 2031.
Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
In the CORALreef AddOn study, roughly 80% of high-risk patients achieved an LDL target of less than 55 mg/dL by 8 weeks.
Please provide your email address to receive an email when new articles are posted on . “In patients with STEMI, early initiation of high-intensity statin therapy, regardless of baseline LDL, is ...
PHILADELPHIA, PA—For high-risk patients with heterozygous familial hypercholesterolemia (HeFH), a novel therapy that shuts off the PCSK9 gene can lower LDL cholesterol, early data from the heart-1 ...
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...
LYON, France — Lerodalcibep, a novel, third-generation anti–proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, helps high-risk patients already receiving maximally tolerated statins to ...
BOSTON -- A PCSK9 inhibitor contributed extra LDL cholesterol lowering as an early add-on to standard high-intensity statins in the acute period of ST-segment elevation MI (STEMI), the small ...
ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL cholesterol levels with just a single, quick, once-monthly dose, the phase III LIBerate-HR trial showed. Lerodalcibep reduced LDL cholesterol by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results